New Drugs Get "Luck Of The Draw" In FDA's First Round Of 18-Month Reviews

"We're not being surprised by anything we are seeing" in the initial batch of FDAAA-mandated post-market assessments, FDA's Boucher says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet